Cancer drug after radiation shows promise in rare thyroid cancer trial
NCT ID NCT05059470
First seen Apr 18, 2026 · Last updated Jun 22, 2026 · Updated 13 times
Summary
This phase 2 trial tested the drug pembrolizumab given after radiation therapy for people with stage IVB anaplastic thyroid cancer, a rare and aggressive cancer. Only 6 participants were enrolled before the study was stopped early. The goal was to see if the combination could delay cancer progression or improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to
If it works, this could point toward a treatment that delays cancer progression or improves survival for people with advanced anaplastic thyroid cancer.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. The cancer is aggressive, and the approach may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.